Acute Myeloid Leukemia (AML) is a complex hematological malignancy characterized by the clonal expansion of hematopoietic stem cells and their precursors. It manifests either as de novo AML or as secondary AML, which can arise following cytotoxic therapy (tAML) or from antecedent hematologic disorders such as myelodysplastic syndromes (MDS). Recent advancements in high-throughput DNA sequencing have revolutionized the diagnostic landscape, enabling the identification of specific genetic signatures that facilitate precise diagnosis, prognostic evaluation, and the development of personalized treatment regimens. These techniques have also been instrumental in detecting germline gene variants associated with AML predisposition. Despite the integration of these methodologies into the latest guidelines by the World Health Organization (WHO), the International Consensus Classification (ICC), and the European LeukemiaNet (ELN), their practical application in real-world clinical settings remains underexplored. There is a pressing need to investigate how these diagnostic advancements can redefine personalized treatment algorithms and improve patient outcomes.
This research topic aims to elucidate the molecular markers that differentiate de novo AML from secondary AML and identify those with significant prognostic value. We seek to highlight the importance of diagnostic and prognostic evaluations in clinical practice, focusing on methods suitable for detecting germline predisposing variants. Additionally, the research will explore novel therapeutic approaches tailored specifically for de novo and secondary AML, aiming to enhance treatment efficacy and patient care.
To gather further insights into the diagnostic and therapeutic innovations in de novo and secondary AML, we welcome articles addressing, but not limited to, the following themes:
- Innovative genetic techniques that enhance the precision of identifying various subcategories of de novo AML, therapy-related AML, and AML secondary to MDS.
- Strategies for recognizing germline predisposing variants associated with AML.
- Exploring the newest therapeutic algorithms tailored for de novo and secondary AML.
- The integration of novel diagnostic methods into clinical practice and their impact on treatment personalization.
- Case studies and reviews that provide insights into the practical application of these innovations in real-world scenarios.
Keywords: clinical decision making, acute myeloid leukemia, Therapy-related AML, AML-MRC, Secondary AML, next generation sequencing
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
